Jun 11, 2026 09:02AM

Jun 9, 2026 09:01AM

Apr 28, 2026 02:42PM

Apr 6, 2026 09:20AM

Mar 24, 2026 09:03AM

Mar 10, 2026 02:59AM

Feb 18, 2026 09:05AM NeuroSense reports 65% death risk reduction in ALS trial

Feb 9, 2026 09:20AM

Oct 14, 2025 09:46AM

May 12, 2025 07:08AM

Apr 24, 2025 09:09AM

Apr 9, 2025 08:30AM

Apr 8, 2025 11:21AM

Jan 6, 2025 09:02AM Neurosense Therapeutics (NRSN) Regains Nasdaq Compliance

Dec 16, 2024 08:13AM

Dec 11, 2024 09:25AM

Dec 2, 2024 08:32AM

Nov 19, 2024 04:18PM

Oct 28, 2024 08:30AM

Oct 15, 2024 09:16AM

Oct 9, 2024 09:02AM Neurosense Therapeutics (NRSN) to File for Early Commercialization of ALS Treatment in Canada

Sep 24, 2024 09:05AM

Sep 24, 2024 09:00AM

Aug 30, 2024 04:30PM

Aug 7, 2024 02:00PM

Aug 1, 2024 09:15AM

Jul 9, 2024 09:27AM

Jul 1, 2024 08:07AM Neurosense Therapeutics (NRSN) Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS

Jun 21, 2024 04:30PM

Nov 28, 2022 11:26AM

413,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All